Unfortunately for Novo Nordisk investors, shares of the Danish pharmaceutical have dived by 36% across that stretch of time. We can't only blame Lilly for this. Given the massive demand for ...

Novo Nordisk has sought strength in numbers in the battle for telehealth obesity drug sales in the US, enlisting the aid of Hims & Hers Health, LifeMD, and Ro to drive direct-to-consumer sales of ...

The US Food and Drug Administration (FDA) has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg oral formulation of Wegovy (semaglutide) intended for chronic weight ...

Novo Nordisk NOVO.B-3.93%decrease; red down pointing triangle said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a ...

Investing.com -- Novo Nordisk (NYSE:NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the company’s New Drug Application for an oral version of Wegovy. If approved, ...

For years, Denmark-based Novo Nordisk (NYSE: NVO) was a fairly traditional develop-and-market pharmaceutical company that escaped notice by many investors. Though listed on American stock ...

Novo Nordisk said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a tense race to get an oral weight-loss medication on ...

MASH prevalence in Canada is projected to rise from 5.2% to 6.5% by 2030. Health Canada review could lead to the first approved treatment for MASH. Don’t miss this list of 10 overlooked stocks ...

Investing.com -- Novo Nordisk (NYSE:NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the company’s New Drug Application for an oral version of Wegovy.